Clinical Trials Browser

Interventional × Hyaluronoglucosaminidase × Plasma cell × Clear all

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT06622005 2025-04-16

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06376214 2024-04-19

Daratumumab for Patients With Light Chain Amyloidosis

Phase NA Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis